THE EFFECT OF DOSE ON THE BIOAVAILABILITY OF ORAL ETOPOSIDE - CONFIRMATION OF A CLINICALLY RELEVANT OBSERVATION

被引：41

作者：

SLEVIN, ML

JOEL, SP

WHOMSLEY, R

DEVENPORT, K

HARVEY, VJ

OSBORNE, RJ

WRIGLEY, PFM

机构：

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1989年 / 24卷 / 05期

关键词：

D O I：

10.1007/BF00304768

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：329 / 331

页数：3

共 24 条

[1]

ALLEN LM, 1982, CANCER CHEMOTH PHARM, V7, P151

[2]

ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71

[3]

ARNOLD AM, 1981, LANCET, V2, P912

[4]

CAVALLI F, 1982, CANCER CHEMOTH PHARM, V7, P81

[5]

CAVALLI F, 1976, CANCER TREAT REP, V62, P463

[6]

DINCALCI M, 1982, CANCER CHEMOTH PHARM, V7, P141

[7]

HANDE KR, 1982, P AM ASSOC CANC RES, V23, P131

[8]

HARVEY VJ, 1986, CANCER CHEMOTH PHARM, V16, P178

[9] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY OF ETOPOSIDE IN PLASMA AND URINE [J].

HARVEY, VJ ;

JOEL, SP ;

JOHNSTON, A ;

SLEVIN, ML .

JOURNAL OF CHROMATOGRAPHY, 1985, 339 (02) :419-423

[10]

HARVEY VJ, 1984, BR J CLIN PHARM, V17, P204

← 1 2 3 →